INCIDENCE OF BREAST CARCINOMA IN PREGNANT AND LACTATING WOMEN

2021 ◽  
pp. 46-47
Author(s):  
Dilpreet Kaur ◽  
Reena Jain ◽  
Sunita Rai ◽  
K.S Mangal
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Breast Cancers ◽  
Histopathological Correlation ◽  
Pregnancy And Lactation ◽  
Common Etiology ◽  
Lactating Females ◽  
Breast Lumps ◽  
A Prospective Study ◽  
In Pregnancy

INTRODUCTION: Breast lumps are a common problem encountered in pregnancy and lactation. These lumps are generally benign like broadenoma, lactating adenoma, mastitis and galactocele. Although rare the possibility of breast cancer (Pregnancy Associated Breast Cancer) should be considered, which is increasing in incidence nowadays. MATERIAL AND METHOD: A prospective study for 18 months was conducted on pregnant and lactating females for evaluating the role of cytology in interpretation of breast cancers. Clinical details, imaging ndings and histopathological correlation (wherever available) was also analyzed. RESULT: 85 breast lumps were identied and benign lesions were the most common etiology seen. Three cases were identied as pregnancy associated breast carcinoma (PABC) constituting 3.5% of all breast lumps. CONCLUSION: Cytology was an effective tool with minimal surgical intervention in identifying the etiology of breast masses in pregnancy and lactation. However, the cytopathologists must be aware of the characteristic patterns seen in breast FNAC smears during pregnancy and lactation and the associated atypia seen in glandular epithelium during this period. Breast carcinoma is the most common malignancy associated with pregnancy. The incidence is low but increasing due to late childbirth. Breast cancer during pregnancy has a similar prognosis to that of breast cancer in young.

Steroid hormone status and HER2/neu expression in pregnancy-associated breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21115-21115 ◽  
Author(s):  
M. Litwiniuk ◽  
E. Breborowicz ◽  
D. Breborowicz ◽  
V. Filas ◽  
J. Breborowicz
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Detection System ◽  
Estrogen Receptor Beta ◽  
Breast Cancers ◽  
Estrogen Receptor Positive ◽  
Formalin Fixed Paraffin Embedded ◽  
Pregnancy And Lactation ◽  
In Pregnancy

21115 Background: Breast cancer occurring during pregnancy or within the first year after delivery is considered to be a pregnancy-associated breast cancer. Some studies have shown a decreased estrogen receptor-positive and progesterone receptor-positive status in pregnant patients with breast cancer, others, however, have not. Moreover, little information is available about the expression of HER2/neu and about the other human estrogen receptor, estrogen receptor beta (ERbeta) in pregnancy-associated breast cancers. The aim of this work was to determine the extent of the expression of ER alpha and beta, progesterone receptor (PgR) and HER2/neu in pregnancy- associated breast cancer. Material and Methods: Formalin-fixed, paraffin embedded tissues from 16 patients with pregnancy- associated breast cancer were used in this study. Immunostaining for ERalpha, ERbeta and PgR was performed using monoclonal antibodies against ERalpha, PgR (DakoCytomation) and against ERbeta (CHEMICON). The EnVision detection system was applied. Tumors were considered to be expressing receptors if a positive reaction (regardless of intensity) could be identified in at least 10% of cells. The HER-2 status was analyzed using HercepTest TM (IHC), and IHC 2+ results were confirmed with FISH test. Results: 44% of the tumors (7/16) were ERalpha and PgR positive. The expression of ERbeta protein was observed in 94% of pregnancy-associated breast cancers. As many as 50% of ERbeta positive tumors showed no expression of ERalpha. Further, 31% (5 of 16) of breast cancers were HER2/neu positive. Conclusions: This frequent expression of ERbeta in pregnancy-associated breast cancer may result from their prodifferentiative functions which increase during pregnancy and lactation. No significant financial relationships to disclose.

scholarly journals Breast Imaging During Pregnancy and Lactation

2019 ◽  
Vol 1 (4) ◽  
pp. 342-351
Author(s):  
Lisa Abramson ◽  
Lindsey Massaro ◽  
J Jaime Alberty-Oller ◽  
Amy Melsaether
Keyword(s):  
Breast Cancer ◽  
Breast Imaging ◽  
Treatment Options ◽  
Nipple Discharge ◽  
Cancer Staging ◽  
Imaging Features ◽  
Breast Cancers ◽  
Bloody Nipple Discharge ◽  
Breast Cancer Staging ◽  
Pregnancy And Lactation

Abstract Breast imaging during pregnancy and lactation is important in order to avoid delays in the diagnosis and treatment of pregnancy-associated breast cancers. Radiologists have an opportunity to improve breast cancer detection by becoming familiar with appropriate breast imaging and providing recommendations to women and their referring physicians. Importantly, during pregnancy and lactation, both screening and diagnostic breast imaging can be safely performed. Here we describe when and how to screen, how to work up palpable masses, and evaluate bloody nipple discharge. The imaging features of common findings in the breasts of pregnant and lactating women are also reviewed. Finally, we address breast cancer staging and provide a brief primer on treatment options for pregnancy-associated breast cancers.

scholarly journals How fatal is breast cancer? A prospective study of breast carcinoma deaths in Tayside

1993 ◽  
Vol 67 (5) ◽  
pp. 1086-1089 ◽  
Author(s):  
DM Parham ◽  
AJ Robertson ◽  
W Guthrie ◽  
J Swanson Beck
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Prospective Study ◽  
A Prospective Study

scholarly journals Mammography in Symptomatic Women Attending a Rapid Diagnosis Breast Clinic: A Prospective Study

2006 ◽  
Vol 88 (3) ◽  
pp. 306-308 ◽  
Author(s):  
MJP Biggs ◽  
D Ravichandran
Keyword(s):  
Breast Cancer ◽  
Significant Proportion ◽  
Management Plan ◽  
Clinical Findings ◽  
Rapid Diagnosis ◽  
Breast Cancers ◽  
Breast Clinic ◽  
Breast Radiologist ◽  
A Prospective Study ◽  
Symptomatic Breast

INTRODUCTION We determined whether it is safe to avoid mammograms in a group of symptomatic women with a non-suspicious history and clinical examination. PATIENTS AND METHODS Symptomatic women aged 35 years or over newly referred to a rapid-diagnosis breast clinic underwent mammography on arrival in the clinic. A breast radiologist reported on the mammograms. An experienced clinician who was unaware of the mammogram findings examined patients and decided whether a mammogram was indicated or not. If not, a management plan was formulated. Mammogram findings were then provided to the clinician and any change to the original management plan as a result of mammography was recorded. RESULTS In two-thirds (67%) of 218 patients, the clinician felt a mammogram was indicated. Half (46%) of these mammograms showed an abnormality; of these abnormal mammograms, 41% were breast cancer. Among the third (n = 71) of mammograms felt not to be indicated, 3 showed abnormalities of which 2 were breast cancer. One cancer was not suspected clinically or mammographically but was diagnosed on cyto/histopathological assessment. CONCLUSIONS A significant proportion of patients attending a symptomatic breast clinic have a non-suspicious history and normal clinical findings on examination. However, even in this group avoiding mammograms risks missing clinically occult breast cancers. It would appear sensible to offer mammograms to all symptomatic women over 35 years of age.

Correlation of an Estrogen Receptor-related Phosphoprotein with Histopathological Features in Breast Cancer

1989 ◽  
Vol 4 (2) ◽  
pp. 95-102
Author(s):  
R.M. Tomasino ◽  
E. Daniele ◽  
R. Nuara ◽  
V. Morello ◽  
M. Salvato ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibody ◽  
Estrogen Receptor ◽  
Breast Carcinoma ◽  
Breast Cancers ◽  
Histopathological Features ◽  
Histological Types ◽  
Biological Meaning ◽  
Er Status

A series of 65 cases of different histological types of breast carcinoma was investigated for the immunohistochemical location of the estrogen receptor-related, 29 kD phosphoprotein using the ER-D5 monoclonal antibody. The ER-D5 response is heterogeneous in relation to some therapeutic limitations and is correlated with histopathological features of the tumors and survival. The main parameters for evaluation of breast cancers are reviewed, both those that are statistically correlated and those that are not apparently always correlated but are known to have considerable biological meaning, such as the ER-status of tumors.

scholarly journals BREAST CANCER IN PREGNANCY AND LACTATION

1978 ◽  
Vol 39 (5) ◽  
pp. 731-734
Author(s):  
Takatoshi NODA ◽  
Masataka KOGA ◽  
Shinya MATSUBARA ◽  
Ryuhei YAMADA ◽  
Akimi MIYATA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer In Pregnancy ◽  
Pregnancy And Lactation ◽  
In Pregnancy

Doppler Flowmetry and the Diagnosis of Breast Lumps

1991 ◽  
Vol 77 (6) ◽  
pp. 468-471 ◽  
Author(s):  
Enrico Gallo ◽  
Emanuele Galante ◽  
Gabriele Martelli ◽  
Marco Stanzani ◽  
Grazia Landi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Flow Analysis ◽  
Mean Value ◽  
Doppler Signal ◽  
Breast Cancers ◽  
Benign Lesions ◽  
Histologic Diagnosis ◽  
Doppler Flowmetry ◽  
Blood Flow Analysis ◽  
Breast Lumps

The aim of the study was to ascertain the reliability of a Doppler signal in the diagnosis of breast cancer. Computerized blood flow analysis was performed on 117 patients who presented with a breast lump at the Division of Diagnostic Oncology of the Istituto Nazionale Tumori of Milan. The values of systolic peak and diastolic frequency were evaluated in relation to the histologic diagnosis. Ten patients had a spontaneous regression of the lump and were excluded from the study. The number of evaluable cases with histologic confirmation was 107: 69 carcinomas and 38 benign lesions. Systolic peak values for the 69 carcinomas ranged from 1500 to 7400 Hz, with a mean value of 3243.4 Hz; diastolic frequency ranged from 200 to 3700 Hz, with mean value of 1413.9 Hz. No diagnostic signals were found in 4 breast cancers (false negatives). Twenty-three of 38 benign lesions (60.5 %) and 65 of 69 malignant nodes (94.2 %) were correctly diagnosed. The Doppler signal with computerized spectral analysis in addition to more specific ultrasonographic parameters could be considered a useful tool in the diagnosis of breast cancer.

Relationship of recent pregnancy and cytologic atypia in the contralateral breast of patients with breast cancer.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 149-149
Author(s):  
E. Revesz ◽  
C. M. Zalles ◽  
D. Ivancic ◽  
K. P. Bethke ◽  
N. M. Hansen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Scoring Systems ◽  
Needle Aspiration ◽  
Contralateral Breast ◽  
Cancer Risk Assessment ◽  
Breast Cancers ◽  
Breast Cancer Risk Assessment ◽  
Cytological Abnormalities ◽  
Cytological Features ◽  
A Prospective Study

149 Background: Although early parity protects against breast cancer later in life, it is a risk factor in the years following pregnancy, particularly when child-bearing is delayed. In a separate study, we have reported that these pregnancy-associated breast cancers (PABC) are more likely to be hormone receptor (HR) negative; we have previously found that random fine needle aspiration (rFNA) of the contralateral breast (CB) frequently have atypia in women with HR negative breast cancer. We now report an analysis of the cytological features of contralateral rFNA in relation to recent parity, with the goal of assessing cytological features which may be risk factors for PABC. Methods: Women with breast cancer undergoing surgery between 2006 and 2008 were enrolled in a prospective study of rFNA of the CB. Cytological analysis was performed on all the samples, using two scoring systems, Masood and Zalles (M and Z). Linear regression analyses were performed relating each score to interval from last pregnancy, stratified for parity, and adjusted for age. Results: Eighty-two patients had rFNA and cytologic analysis. The parous group’s (n=52) interval since last pregnancy was inversely correlated with the overall M score (p=0.034); pleomorphism and (p=0.047 and p=0.013 respectively). M score was also related to age at last pregnancy (p=0.026) as were pleomorphism and chromatin pattern (p=0.044 and 0.035 respectively). In the nulliparous group (n=30), there were no significant relationships between any of the cytological parameters or age. Conclusions: The CB of women with recent parity display specific cytological abnormalities that are related to risk of breast cancer, particularly HR negative breast cancer. This observation affords the opportunity to further evaluate rFNA as a tool for breast cancer risk assessment following pregnancy, and to identify molecular correlates of nuclear cytological abnormalities that may serve as targets for prevention of ER negative breast cancer.

The Management of breast carcinoma in pregnancy and lactation

1982 ◽  
Vol 21 (3) ◽  
pp. 179-182 ◽  
Author(s):  
E. Hornstein ◽  
Y. Skornick ◽  
R. Rozin
Keyword(s):  
Breast Carcinoma ◽  
Pregnancy And Lactation ◽  
In Pregnancy

scholarly journals TRAIL-Induced Apoptosis in TRAIL-Resistant Breast Carcinoma Through Quercetin Cotreatment

2018 ◽  
Vol 12 ◽  
pp. 117822341774985 ◽  
Author(s):  
Jasmine M Manouchehri ◽  
Katherine A Turner ◽  
Michael Kalafatis
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Human Tumor ◽  
Breast Cancers ◽  
Treatment Regimens ◽  
Efficacious Treatment ◽  
Induced Apoptosis ◽  
Necrosis Factor ◽  
Mcf 7

Breast cancer is the most commonly diagnosed cancer in women. There is a continued interest for the development of more efficacious treatment regimens for breast carcinoma. Recombinant human tumor necrosis factor–related apoptosis-inducing ligand (rhTRAIL) shows potential as a potent anticancer therapeutic for the treatment of breast cancer, whereas displaying minimal toxicity to normal cells. However, the promise of rhTRAIL for the treatment of breast cancer is dismissed by the resistance to rhTRAIL-induced apoptosis exhibited by many breast cancers. Thus, a cotreatment strategy was examined by applying the natural compound quercetin (Q) as a sensitizing agent for rhTRAIL-resistant breast cancer BT-20 and MCF-7 cells. Quercetin was able to sensitize rhTRAIL-resistant breast cancers to rhTRAIL-induced apoptosis as detected by Western blotting through the proteasome-mediated degradation of c-FLIPL and through the upregulation of DR5 expression transcriptionally. Overall, these in vitro findings establish that Q is an effective sensitizing agent for rhTRAIL-resistant breast cancers.

Sign in / Sign up

Export Citation Format

Share Document